213 related articles for article (PubMed ID: 16982553)
1. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response.
Horsman MR; Nielsen T; Østergaard L; Overgaard J
Acta Oncol; 2006; 45(7):876-80. PubMed ID: 16982553
[TBL] [Abstract][Full Text] [Related]
2. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
3. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
Horsman MR; Overgaard J
Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
[TBL] [Abstract][Full Text] [Related]
5. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Horsman MR
Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
[TBL] [Abstract][Full Text] [Related]
6. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
7. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC.
Petersen C; Zips D; Krause M; Völkel W; Thames HD; Baumann M
Radiother Oncol; 2005 Mar; 74(3):331-6. PubMed ID: 15763315
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
Kirichenko AV; Rich TA; Newman RA; Travis EL
Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
[TBL] [Abstract][Full Text] [Related]
10. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo.
Jordan A; Scholz R; Wust P; Fähling H; Krause J; Wlodarczyk W; Sander B; Vogl T; Felix R
Int J Hyperthermia; 1997; 13(6):587-605. PubMed ID: 9421741
[TBL] [Abstract][Full Text] [Related]
11. 31P NMR spectroscopy can predict the optimum interval between fractionated irradiation doses.
Murata O; Sakurai H; Mitsuhashi N; Hasegawa M; Yamakawa M; Kurosaki H; Hayakawa K; Niibe H
Anticancer Res; 1998; 18(6A):4297-301. PubMed ID: 9891481
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
13. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice.
Schütze C; Bergmann R; Yaromina A; Hessel F; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
Radiother Oncol; 2007 Jun; 83(3):311-5. PubMed ID: 17502117
[TBL] [Abstract][Full Text] [Related]
14. Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum.
Lukacova S; Khalil AA; Overgaard J; Alsner J; Horsman MR
Int J Radiat Biol; 2005 Dec; 81(12):937-44. PubMed ID: 16524849
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
16. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa.
Gehrisch A; Dörr W
Strahlenther Onkol; 2007 Jan; 183(1):36-42. PubMed ID: 17225944
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
[TBL] [Abstract][Full Text] [Related]
18. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo.
Krause M; Wohlfarth J; Georgi B; Pimentel N; Dorner D; Zips D; Eicheler W; Hessel F; Short SC; Joiner MC; Baumann M
Int J Radiat Biol; 2005 Oct; 81(10):751-8. PubMed ID: 16449082
[TBL] [Abstract][Full Text] [Related]
19. Oxygen cathode measurements and radiation response in tumour-bearing mice treated with misonidazole.
Davies RW; Hall WS
Br J Cancer Suppl; 1978 Jun; 3():154-8. PubMed ID: 277216
[TBL] [Abstract][Full Text] [Related]
20. Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy.
Mahmood U; Alfieri AA; Thaler H; Cowburn D; Koutcher JA
Cancer Res; 1994 Sep; 54(18):4885-91. PubMed ID: 8069854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
